Concepedia

Matthew J. Clements

MJ

Statistics

Publications

5

Citations

152

H-Index

5

Active since

2008

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Matthew J. Clements is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

Publications per year

2008–2017

5

Publications

5

Discovery of <i>N</i>-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

John S. Debenham, Christina B. Madsen-Duggan, Matthew J. Clements et al. · Journal of Medicinal Chemistry · 2016 · 54 citations · Full text

, , +13

Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor

Richard Z. Chen, Andrea Frassetto, Julie Lao et al. · European Journal of Pharmacology · 2008 · 41 citations

, , +11

Design and Synthesis of Novel, Selective GPR40 AgoPAMs

Christopher W. Plummer, Matthew J. Clements, Helen Chen et al. · ACS Medicinal Chemistry Letters · 2017 · 34 citations · Full text

, , +15

The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics

Harry R. Chobanian, Yan Guo, Barbara Pio et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 13 citations · Full text

, , +10

Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors

John S. Debenham, Thomas H. Graham, Andreas Verras et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 10 citations · Full text

, , +8

1–5 of 5